A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly and plaintiffs abandon proposed US$13.5M settlement regarding alleged overpricing of insulin; the move follows a court ruling against certifying specific state-classes in the case

INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "PEPTIDES FOR INCRETIN SYNTHESIS"

GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B

Abbott reports Q1 organic sales growth, excluding COVID-19 related sales, of 10.8%; medical device and established pharmaceutical sales grew 14% during the quarter

Three US Senators to question Novo Nordisk over the discontinuation of Levemir, a long-acting insulin, just before a significant price cut was due to take effect; over seven million patients in the US rely on insulin

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count